

DAFTAR PUSTAKA

1. Febriani A, Furqon A. Metastasis Kanker Paru. *Jurnal Respirasi*. 2020;4(3):94.
2. Global Burden of Cancer at the World Health Organization. 2021;
3. Robot RY, Durry MF, Kairupan CF. Morfologi, Patogenesis, dan Imunoterapi Kanker Paru Tipe Adenokarsinoma. *Medical Scope Journal*. 2021;3(1):74.
4. Sugiharto S, Simanjuntak RAP, Larissa O. Kanker Paru, Faktor Risiko Dan Pencegahannya. *Prosiding SENAPENMAS*. 2021;613.
5. Wheless L, Brashears J, Alberg AJ. Epidemiology of lung cancer. *Lung Cancer Imaging*. 2013;1–15.
6. Paulsen F, Waschke J. *Sobotta Clinical Atlas of Human Anatomy*, one volume, English. Elsevier Health Sciences; 2019.
7. Mescher AL. *Junqueira's basic histology: text and atlas*. 2013;
8. Hall JE, Hall ME. *Guyton and Hall textbook of medical physiology e-Book*. Elsevier Health Sciences; 2020.
9. Sherwood L. *Human physiology*. BROOKS; 2019.
10. Sharma R. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. *International Journal of Clinical Oncology*. 2022;27(4):665–75.
11. Bade BC, Cruz CSD. Lung cancer 2020: epidemiology, etiology, and prevention. *Clinics in chest medicine*. 2020;41(1):1–24.
12. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics. *CA: a cancer journal for clinicians*. 2016;66(4):271–89.
13. Suraya A, Nowak D, Sulistomo AW, Icksan AG, Berger U, Syahrudin E, et al. Excess risk of lung cancer among agriculture and construction workers in Indonesia. *Annals of Global Health*. 2021;87(1).

14. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. *Contemporary Oncology/Współczesna Onkologia*. 2021;25(1):45–52.
15. Fiorelli A, D’Andrilli A, Carlucci A, Vicidomini G, Loizzi D, Ardò NP, et al. Prognostic factors of lung cancer in lymphoma survivors (the LuCiLyS study). *Translational Lung Cancer Research*. 2020;9(1):90.
16. Zhang Y, Luo G, Etxeberria J, Hao Y. Global patterns and trends in lung cancer incidence: a population-based study. *Journal of Thoracic Oncology*. 2021;16(6):933–44.
17. Pavlisko EN, Roggli VL. Lung cancer: Clinical findings, pathology, and exposure assessment. *Occupational Cancers*. 2020;205–26.
18. Azhdarpoor A, Hoseini M, Shahsavani S, Shamsedini N, Gharehchahi E. Assessment of excess lifetime cancer risk and risk of lung cancer due to exposure to radon in a middle eastern city in Iran. *Radiation Medicine and Protection*. 2021;2(03):112–6.
19. Agarwal P, Chaudhari S, Jagati A, Rathod S, Neazee S. Clinical spectrum of pregnancy related dermatoses in a tertiary care hospital in western India. *Natl J Community Med*. 2020;11:450–5.
20. Kushwah AS, Banerjee M. Genetics Of Glutathione S-transferases and Complex Diseases. Igor Azevedo Silva, *Glutathione S-Transferases: Structure, Functions and Clinical Aspects*, Nova Science Publishers Inc New York USA. 2020;1–38.
21. North CM, Christiani DC. Women and lung cancer: what is new? In Elsevier; 2013. p. 87–94.
22. Shen H, Zhu M, Wang C. Precision oncology of lung cancer: genetic and genomic differences in Chinese population. *NPJ precision oncology*. 2019;3(1):14.
23. Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: A review for general practitioners in oncology. *Current Oncology*. 2022;29(3):1828–39.

24. Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. *Lung Cancer*. 2015;87(2):193–200.
25. Gayen S. Malignant pleural effusion: presentation, diagnosis, and management. *The American Journal of Medicine*. 2022;
26. Shojaee S, Roy-Chowdhuri S, Safi J, Grosu HB. Cytologic Investigations for the Diagnosis of Malignant Pleural Effusion in Non-small Cell Lung Cancer: State-of-the-art Review for Pulmonologists. *Journal of Bronchology & Interventional Pulmonology*. 2021;28(4):310–21.
27. Asciak R, Bedawi EO, Bhatnagar R, Clive AO, Hassan M, Lloyd H, et al. British Thoracic Society Clinical Statement on pleural procedures. *Thorax*. 2023;78(Suppl 3):s43–68.
28. Klein-Weigel PF, Elitok S, Ruttloff A, Reinhold S, Nielitz J, Steindl J, et al. Superior vena cava syndrome. *Vasa*. 2020;
29. Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. *International journal of molecular sciences*. 2021;22(16):8661.
30. Aljohaney AA. Real time endobronchial ultrasound transbronchial needle aspiration for the diagnosis of tuberculous intrathoracic lymphadenopathy: Saudi Arabian Western region experience. *Saudi Medical Journal*. 2023;44(2):178.
31. Latimer KM, Mott TF. Lung cancer: diagnosis, treatment principles, and screening. *American family physician*. 2015;91(4):250–6.
32. Sager O, Dincoglan F, Demiral S, Gamsiz H, Uysal B, Ozcan F, et al. Optimal timing of thoracic irradiation for limited stage small cell lung cancer: Current evidence and future prospects. *World Journal of Clinical Oncology*. 2022;13(2):116.
33. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of

- tumors of the lung, pleura, thymus, and heart. *Journal of Thoracic Oncology*. 2015;10(9):1240–2.
34. Pandi A, Mamo G, Getachew D, Lemessa F, Kalappan V, Dhiravidamani S. A brief review on lung cancer. *Int J Pharma Res Health Sci*. 2016;4:907–14.
 35. Chang JT, Anic GM, Rostron BL, Tanwar M, Chang CM. Cigarette smoking reduction and health risks: a systematic review and meta-analysis. *Nicotine and Tobacco Research*. 2021;23(4):635–42.
 36. US Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general. 2014;
 37. Shankar A, Dubey A, Saini D, Singh M, Prasad CP, Roy S, et al. Environmental and occupational determinants of Lung Cancer. *Translational Lung Cancer Research*. 2019;8(S1)
 38. Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, et al. Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. *Japanese journal of clinical oncology*. 2021;51(8):1269–76.
 39. Cui R, Wei C, Li X, Jiang O. A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer. *Medicine*. 2022;101(47).
 40. PS V, MH G, Krishna KJ, CD S, AL L. Outcomes and Prognostic Factors of Extensive Stage Small Cell Lung Cancer: A Retrospective Study. *South Asian Journal of Cancer*. 2023;
 41. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology: official journal of the European Society for Medical Oncology*. 2018;29: 192–237.
 42. Cancer incidence by age. *Cancer Research UK*. 2015

43. Aisah SKN, Haryati H, Bakhriansyah M. Profil Penderita Kanker Paru Primer Di RSUD Ulin Banjarmasin Tahun 2006-2011. Berkala Kedokteran. 2013;9(2):169–80.
44. Clark SB, Alsubait S. Non Small Cell Lung Cancer. PubMed. Treasure Island (FL): StatPearls Publishing; 2020.
45. Logawathi, Satthiyabalan A/L Sivabalan. Karakteristik Penderita Kanker Paru di RSUP Haji Adam Malik Medan Tahun 2016-2018. 2016;

